Navigation Links
Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62
Date:5/2/2013

three months ended March 31, 2013 as compared to adjusted earnings of $224.5 million for the prior year comparable period.

EBITDA, which is defined as net income (excluding the non-controlling interest and income from equity method investees) plus income taxes, interest expense, depreciation and amortization, was $350.5 million for the quarter ended March 31, 2013, and $368.5 million for the comparable prior year period. After adjusting for certain items as further detailed below, adjusted EBITDA was $443.4 million for the current three-month period and $411.2 million for the comparable prior year period. 

Cash Flow Adjusted cash provided by operating activities was $90 million for the three months ended March 31, 2013, compared to $69 million for the comparable prior year period. On a GAAP basis, cash provided by operating activities was $88 million for the three months ended March 31, 2013, compared to a cash usage of $107 million for the comparable prior year period. Capital expenditures were approximately $53 million in the current year as compared to approximately $36 million in the same prior year period.

During the three months ended March 31, 2013, the Company completed a share repurchase program by purchasing approximately 16.3 million shares of common stock for approximately $500 million.

Non-GAAP Financial Measures Mylan is disclosing non-GAAP financial measures when providing financial results. Primarily due to acquisitions, Mylan believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with accounting principles generally accepted in the U.S. (GAAP). In addition to disclosing its financial results determined in accordance with GAAP, Mylan is disclosing certain non-GAAP results that exclude items such as amortiza
'/>"/>

SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Mylan Launches Generic Version of Zyprexa® Tablets
2. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
3. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
4. Mylan Launches Generic Lipitor® in Five European Countries
5. Mylan Launches Generic Version of Plavix® Tablets
6. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
7. Mylan Launches Generic Version of Viramune® Tablets
8. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
9. Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovions Brovana® Product
10. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
11. Mylan Launches Generic Version of Lipitor®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015 Par Pharmaceutical Companies, Inc. ... on Friday, August 7, 2015 at 9:00 a.m. EDT ... quarter ended June 30, 2015.  Par is privately held ... public in its filings with the Securities and Exchange ... its website by following the instructions at http://www.parpharm.com/financialinfo ...
(Date:8/3/2015)... 3, 2015 Ortho Clinical Diagnostics (OCD) today ... Chief Corporate Brand and Communications Officer, effective immediately. As ... Bouryal will lead the company,s worldwide corporate brand and ... to an independent company by adding sites in countries ... Chief Executive Officer Dr. Martin Madaus . ...
(Date:8/3/2015)... 2015 According to a ... "Global Market Study on Physiotherapy Equipment - ... by 2022", the global physiotherapy equipment market is estimated to ... 2015 and is expected to grow at a ... account for US$23.7 Bn by 2022. View ...
Breaking Medicine Technology:Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4
... TROY, Mich., Oct. 25, 2011 CareTech Solutions, an ... for over 180 U.S. hospitals announced today that the ... information officer, Detroit Medical Center (DMC), Vanguard Health System ... the 2011 College of Health Information Management Executives (CHIME) ...
... Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the ... today the contractual agreements for S1P1 lead compounds, AMG ... a sealed bid sale.   AMG-369, AMG-277 ... as part of License Agreement between Amgen and Epix ...
Cached Medicine Technology:Detroit Medical Center Shares Smart Room Case Study at CHIME 2011 Fall CIO Forum 2Contractual Agreements Revealed for S1P1 Lead Compounds, AMG 369 and AMG 277, Offered for Sale at a December 8, 2011 Sealed Bid Sale 2
(Date:8/3/2015)... ... August 03, 2015 , ... ... to Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions that ... care costs. , Annually, more than 8.6 million adverse drug events are ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in ... patients in need. Most people know that general health emergencies, such as broken arms ... amount of people know where to turn to during a dental emergency. This is ...
(Date:8/3/2015)... Florida (PRWEB) , ... August 03, 2015 , ... ... for Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis ... , Fifty-five percent of respondents said they agreed or strongly agreed that the ...
(Date:8/3/2015)... ... , ... The U.S. Food and Drug Administration (FDA) recently approved a new ... which occurs naturally in the body and helps absorb and breakdown fat cells. Previously, ... body. These are invasive procedures and very expensive for most people. Now with Kybella, ...
(Date:8/3/2015)... ... ... Illinois Health & Science (IHS) has completed the purchase of IBA Molecular ... IBAM NA’s cyclotron sites and research and development facilities. , “We are ... as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President and CEO ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2
... researchers from Stanford have identified the nitric oxide gas as ... resulting in the development of an embryo.He says,it begins with ... ,The research is based on the sex lives of ... in the Pacific Ocean just a few yards from Epel's ...
... flowing smoothly after angioplasty shows surprising success in early testing. ... the drug-coated stent. //In testing on 50 patients over 3 ... ,More than 2 million Americans undergo angioplasty annually, ... most of them if these promising results hold up in ...
... in arresting the dental plaque bacteria believed to be ... report at the American Association// for Dental Research annual ... produces hydrogen peroxide is the key to the antimicrobial ... associate professor of biochemistry at the University of Waikato, ...
... Scientists form Johns Hopkins University School of Medicine have recently ... in the brain that lets us stop smelling something, even ... in a recent issue of the journal Science show that ... receptor cells.The main job of these neurons is to detect ...
... Corp is close to signing a deal to acquire the ... fellow US drugmaker Abbott Laboratories Inc. An industry source who ... in the next few days to buy the stake in ... senior Abbott officials from the company’s regional office in singapore ...
... undergoing open heart surgery for patients in their mid-eighties ... and advisable for the elderly.// ,According to Dr. ... University ,open heart surgery, if indicated, is safe and ... and head of cardiac surgery at Southeastern Healthcare in ...
Cached Medicine News:Health News:The route to fertilization, 2Health News:Heart Surgery Is Getting Safer for the Old 2
... Oxygen Conservation Device. Bypass ... ,6200 Accessories: , OCD870C ... CGA 540 Regulator , OCD2001-18 ... Booklet , CP2140 Vertical M-6 ...
... Catheter with Accutrol is similar in design ... that it incorporates a temperature probe at ... temperature probe can accurately determine the patient's ... provides temperature accuracy comparable to a pulmonary ...
... These markers are available with 16 or 24 ... 6.5mm diameter, and an outer 9.5mm diameter. The markers ... in one single step for a 16 or 24 ... outer points on the cornea to achieve a precise ...
... Through A 1.0mm Incision., ,Special Direct Acting ... Improved ... Approach., ,Recessed Jaws For Improved Sub-Incisional Flap ... Jaws During Sterilization., ,Reusable, Autoclaveable, Guaranteed For ...
Medicine Products: